Additional Positive Efficacy Data with BI-1808 monotherapy from Ph 2a anti-TNFR2 program Announced September 17, 2024
FDA approves BORUZU, a new presentation of bortezomib for ready-to-use subcutaneous administration or IV administration September 10, 2024
Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Ph 1b Trial in DLBCL announced September 10, 2024
NMPA approves Supplemental BLA for Carteyva® in Adult Patients with R/R Mantle Cell Lymphoma September 3, 2024
Randomized controlled trial of Nana-val in EBV-positive PTCL patients planned to begin in the second half of 2025 to support potential registration August 27, 2024
EU Approves TEPKINLY® (epcoritamab) for the Treatment of Adults with R/R Follicular Lymphoma August 27, 2024
Positive Topline Results from Tafasitamab (Monjuvi®) trial in R/R Follicular Lymphoma Announced August 22, 2024
FDA provides IND requirements for the development of ALA-101 in first-inhuman clinical trials for lymphoma and leukaemia August 13, 2024
FDA Approves LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with R/R Cutaneous T-Cell Lymphoma August 13, 2024
FDA Fast Track Designation Granted to Soquelitinib for Treatment of Patients with R/R PTCL August 6, 2024
Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma July 17, 2024
HREC Approval and CTN Clearance granted from the TGA to Commence a Ph 1 Clinical Trial for INT2104 for B Cell Malignancies July 17, 2024
Three Community Cancer Centers Activated as First Sites for the Pivotal Ph 2 ALPHA3 Trial of Cemacabtagene Ansegedleucel (cema-cel) as 1L Consolidation Treatment for Patients with LBCL July 9, 2024
NMPA accepts NDA for Tazemetostat for the Treatment of R/R Follicular Lymphoma with Priority Review Status July 9, 2024
US FDA Grants Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with R/R Follicular Lymphoma July 1, 2024
Odronextamab Recommended for EU Approval by the CHMP to Treat R/R Follicular Lymphoma and DLBCL July 1, 2024
Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with R/R Follicular Lymphoma July 1, 2024
Pivotal Ph 2 Trial of Cemacabtagene Ansegedleucel (cema-cel) as 1L Treatment in Large B-Cell Lymphoma (LBCL) patients initiated June 25, 2024
Calquence + chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. SOC in patients with untreated mantle cell lymphoma in ECHO Ph 3 trial June 18, 2024
